Oxford BioTherapeutics
  • ABOUT
    • COMPANY OVERVIEW
    • SENIOR LEADERSHIP >
      • MANAGEMENT
      • BOARD OF DIRECTORS
      • INVESTORS
    • OFFICES & LABS
  • PIPELINES
  • IO DISCOVERY
    • IMMUNE CHECKPOINT TARGETS
    • IO ANTIBODY ENGINEERING
  • CAREERS
  • NEWS
  • CONTACT

Harnessing immune cells to cure cancer 

Redefining the cancer-immune synapse for
novel immune checkpoint mechanisms 
NOVEL IO DISCOVERIES
Pipelines

​Immunotherapies for Cancer

Oxford BioTherapeutics (OBT) is a clinical stage oncology company committed to the discovery and development of novel therapies for various cancer types.

OBT's approach, based on our proprietary immune-oncology and antibody-drug conjugate pipelines, is to re-engage and recruit the body's immune system to attack cancer cells. We are therefore able to provide targeted treatment strategies to patients most in need, including those who have failed to respond to conventional treatments.
​
To help bring about this much awaited transformation in the cancer therapy landscape, we have built one of the world’s largest integrated oncology immune cell surface protein libraries. This, together with our dedicated team of international immuno-oncology experts and our broad clinical alliances, have led to our discovery of multiple never-before identified cancer-immune cell targets, and the subsequent development of therapies based on these findings. 



OVERVIEW

Fully funded clinical ADC/C pipeline

Portfolio approach –  up to five programs
 
De-risked to Ph II/ POC through partnership

Broader innovative IO  pipeline

​ Critical discovery: Major novel immune escape mechanism
Discovery of novel IO receptors & ligands

300+ patents
100 granted



MILESTONES

​ADC OBT076 dose escalation clinical trial 
US multi-site trial - PhI ongoing

​ADCC Monoclonal Antibody MEN1112 
European PhI ongoing for AML

ADC MEN1309 in TNBC, DLBCL & other
European Phase I ongoing


Upto €800 million investment from Menarini Ltd.
Clincal testing of upto 5 mAbs
OBT retains US & Japanese rights 


IO pipeline
​Multiple programs in pre-clinical development
 


GLOBAL HEADQUARTERS

94a Innovation Drive  
Milton Park
Abingdon OX14 4RZ  
UK
+44 (0) 1235 861770 


CONTACT US

US OPERATIONS

San Jose Biocenter  
5941 Optical Court
San Jose, CA 95138  
USA
+1-408-960-7461 


CONTACT US

Privacy Policy

Legal Notice

Site Map

© 2017 Oxford BioTherapeutics All Rights Reserved
  • ABOUT
    • COMPANY OVERVIEW
    • SENIOR LEADERSHIP >
      • MANAGEMENT
      • BOARD OF DIRECTORS
      • INVESTORS
    • OFFICES & LABS
  • PIPELINES
  • IO DISCOVERY
    • IMMUNE CHECKPOINT TARGETS
    • IO ANTIBODY ENGINEERING
  • CAREERS
  • NEWS
  • CONTACT